Public Puts Pressure on the FDA to Not Ban Bioidentical HormonesThanks to your activism, the FDA has agreed to study bioidentical hormone replacement therapy. But the threat to hormones still looms. For months now, we’ve been telling you about the FDA’s attack on estriol, progesterone, and other bioidentical hormones that are made for individual patients at specialized pharmacies. Now, thanks to the activism of ANH members and other stakeholders, the agency has recently announced that they have asked the National Academies of Science, Engineering, and Medicine (NASEM) to conduct a study on bioidentical hormone replacement therapy (BHRT). This is a qualified victory: it shows that the FDA feels enough pressure from the public that they can’t ban bioidentical hormones outright. But the fight is far from over, and we must remain vigilant to ensure the future of bioidentical hormone replacement therapy (BHRT).